Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC.PIRS · Entity 4452 | Chief Development Officer | February 26, 2019 | February 28, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PALVELLA THERAPEUTICS, INC.
Report date February 26, 2019 · Filed February 28, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.09 · Expires 2029-02-26 | Direct | 96,500 |
Reported balance
After 2019-02-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-02-26 · Grant · Acquired 96,500 · Balance 96,500 F1: The option vests as to 25% of the option shares on February 26, 2020 and vests as to an additional 6.25% of the option shares at the end of each successive three-month period thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests as to 25% of the option shares on February 26, 2020 and vests as to an additional 6.25% of the option shares at the end of each successive three-month period thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 26, 2019 Filed Feb 28, 2019 22:25 UTC | PALVELLA THERAPEUTICS, INC. PIRS · Entity 4452 | GrantStock Option (Right to Buy) · Derivative | 96,500 | $0.00 Strike: $3.09 | $0.00 |
DisclosureSEC source: 0001562180-19-001488 · primarydocument.xml · derivative · entry 1 Matis Louis · CIK 0001650991 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,500 Underlying: Common Stock · 96,500 shares Expires 2029-02-26 F1 · derivative.exercise_date: The option vests as to 25% of the option shares on February 26, 2020 and vests as to an additional 6.25% of the option shares at the end of each successive three-month period thereafter. Read SEC document |
| February 20, 2018 Filed Feb 27, 2018 00:16 UTC | PALVELLA THERAPEUTICS, INC. PIRS · Entity 4452 | GrantStock Options (Right to buy) · Derivative | 100,000 | $0.00 Strike: $8.56 | $0.00 |
DisclosureSEC source: 0001562180-18-001253 · primarydocument.xml · derivative · entry 1 Matis Louis · CIK 0001650991 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2028-02-20 F1 · derivative.exercise_date: The option vests as to 25% of the option shares on January 1, 2019 and vests as to an additional 6.25% of the option shares at the end of each successive three-month period thereafter. Read SEC document |
| February 23, 2017 Filed Mar 6, 2017 11:50 UTC | PALVELLA THERAPEUTICS, INC. PIRS · Entity 4452 | GrantStock option (Right to buy) · Derivative | 145,000 | $0.00 Strike: $1.99 | $0.00 |
DisclosureSEC source: 0000899243-17-006558 · doc4.xml · derivative · entry 1 Matis Louis · CIK 0001650991 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,000 Underlying: Common Stock · 145,000 shares Expires 2027-02-23 F1 · derivative.exercise_date: The option vests as to 25% of the option shares on January 1, 2018 and vests as to an additional 6.25% of the option shares at the end of each successive three-month period thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.